There are 2789 resources available
1119P - Genomic alterations of neuroendocrine carcinoma originated from female genital tract
Presenter: MeiYu Fang
Session: ePoster Display
1236P - Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
Presenter: Arsela Prelaj
Session: ePoster Display
1165P - Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
Presenter: Parneet Cheema
Session: ePoster Display
1122TiP - A phase II trial to evaluate the safety and dosimetry of [<sup>177</sup>Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)
Presenter: Mark Gaze
Session: ePoster Display
1125P - Analytical assessment of a diagnostic immunohistochemical assay for the detection of folate receptor-ɑ in epithelial ovarian cancers
Presenter: Racheal James
Session: ePoster Display
1240P - Targeting exon 18 EGFR alterations in non-small cell lung cancer: A patient-level analysis of published data
Presenter: Mehmet Goksu
Session: ePoster Display
1241P - Effects of different brain radiotherapy strategies based on lung-molGPA stratification on the prognosis of patients with brain metastases of EGFR-mutant lung adenocarcinoma
Presenter: Guangchuan Deng
Session: ePoster Display
1248P - Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?
Presenter: Hasan Kobat
Session: ePoster Display
1249P - Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight
Presenter: Tetsunari Hase
Session: ePoster Display
1250P - Differences of immune microenvironment among NSCLC patients with various KRAS mutation types
Presenter: Kun Wang
Session: ePoster Display